Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis : Benefit/risk following review of trial and post-marketing data
-
Coles, Alasdair J. (University of Cambridge)
;
Jones, Joanne L. (University of Cambridge) ;
Vermersch, Patrick (Université de Lille) ;
Traboulsee, Anthony (University of British Columbia) ;
Bass, Ann D. (Neurology Center of San Antonio) ;
Boster, Aaron (Boster Center for Multiple Sclerosis) ;
Chan, Andrew (University of Bern) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Fernández, Óscar (Hospital Regional Universitario de Málaga) ;
Giovannoni, Gavin (Queen Mary University of London) ;
Kubala Havrdova, Eva (Charles University) ;
LaGanke, Christopher (North Central Neurology Associates) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Oreja-Guevara, Celia (Universidad Complutense de Madrid) ;
Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ;
Wiendl, Heinz (University of Münster) ;
Ziemssen, Tjalf (Dresden University of Technology) ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
